Gut-microbiome-derived metabolite · Fact sheet
Urolithin A
Also known as UA · pomegranate-derived postbiotic
Urolithin A has early human evidence for target engagement and selected muscle-endurance outcomes, but it is not an FDA-approved drug for aging, muscle loss, mitochondrial disease, or immune decline. Trials have been small and commonly industry sponsored.
What is Urolithin A?
Urolithin A is a metabolite made when certain gut bacteria process ellagitannins found in foods such as pomegranates and walnuts.
It is studied as a trigger of mitophagy, the cellular process that removes damaged mitochondria.
Benefits people look for
Mitochondrial quality control is relevant to aging, muscle function, and immune-cell biology.
Human studies provide a stronger translational base than many frontier compounds, but sponsor involvement, modest samples, and mixed endpoints call for independent replication.
What the evidence supports
- A controlled older-adult trial reported better muscle endurance and biomarker changes but did not improve its primary walking-distance or ATP-production outcomes over placebo.
- Other sponsored trials report muscle-performance or immune-cell signals that need confirmation in larger independent studies.
All research areas
- Mitophagy and mitochondrial biomarkers
- Muscle endurance and physical performance
- Age-related immune changes
- Healthy-aging biology
Anecdotal reports & lived experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.
No attributable personal reports are summarized here yet. The benefits above describe research interests; the side effects below come from the cited medical sources.
We do not fill this gap with unsourced testimonials or estimated success rates.
Side effects & risks
- Short trials generally reported similar adverse-event rates to placebo, but sample sizes were too small to define uncommon harms.
- Several pivotal human studies involved the ingredient developer or sponsor, a conflict that does not invalidate results but increases the value of independent replication.
- Commercial supplement quality may not match trial material.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research: how strong is it?
Early human evidenceRandomized human studies show biochemical target engagement and some secondary muscle or immune signals. In one older-adult trial, the primary walking-distance and ATP-production outcomes were not significantly better than placebo.
Selected research to read
Trial with negative primary walking and ATP outcomes but positive muscle-endurance and biomarker findings.
Industry-sponsored study of muscle performance and mitochondrial biomarkers.
Early study establishing bioavailability, short-term tolerability, and biomarker effects.
FDA approval & research status
Urolithin A is not an FDA-approved drug for any aging, muscle, mitochondrial, or immune indication. Supplement availability is not evidence of FDA-reviewed effectiveness.
No FDA-approved use is documented in the records summarized on this page.
No FDA-approved drug use
Urolithin A has human supplement-style trials and biomarker outcomes, but no FDA-approved drug indication for mitochondrial health, muscle function, or aging.
This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.
What we still don’t know
- Whether effects persist or translate into less disability or disease
- Whether independent trials reproduce sponsor-linked findings
- Long-term safety across diverse populations
- Which people, if any, have a clinically meaningful response
The takeaway
Urolithin A has promising early human work, but mixed endpoints and a sponsor-heavy evidence base make it a research candidate—not a proven anti-aging therapy.
Sources & further reading
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- 1pubmedRandomized urolithin A trial in older adults
Trial with negative primary walking and ATP outcomes but positive muscle-endurance and biomarker findings.
- 2pubmedRandomized trial in middle-aged adults
Industry-sponsored study of muscle performance and mitochondrial biomarkers.
- 3pubmedFirst-in-human urolithin A study
Early study establishing bioavailability, short-term tolerability, and biomarker effects.
- 4fdaFDA: what ‘FDA approved’ does and does not mean
FDA explains that dietary supplements are not approved for safety and effectiveness before marketing.